Expired activity
Please go to the PowerPak homepage and select a course.

The Role of Immune Checkpoint Inhibitors in the Treatment of Genitourinary Cancers: An Interprofessional Perspective on Guideline Updates

Provided by American Academy of CME, Inc.

This educational activity is supported by an educational grant from Merck.

Release date

September 30, 2020

Expiration date

September 30, 2021

Estimated time to complete

1.5 hours

Activity Description

The landscape of genitourinary cancer therapy is evolving. As treatment options expand and are integrated into treatment regimens, and guidelines are updated to reflect these advances, there is an ongoing need for the members of the care team to engage in continuing education in this area. Additionally, as the pandemic continues, it’s important that clinicians recognize and apply strategies for reducing the risk of COVID-19 infection in vulnerable patients.

Faculty Educators

Marcus S. Flores, PharmD, BCPS, BCOP
Clinical Pharmacist, Oncology
Hackensack Meridian Health Cancer Care
Jersey Shore University Medical Center

Marcus S. Flores, PharmD, BCPS, BCOP is an oncology clinical pharmacist at Jersey Shore University Medical Center, a tertiary care academic medical center that is part of the Hackensack-Meridian Health network. Prior to taking his current position, he completed a PGY-1 residency program in Cleveland, Ohio at MetroHealth Medical Center. He has also since gained his board certification in both pharmacotherapy and oncology pharmacy. In his current role, he rounds as part of an inpatient team on a diverse group of patients with various malignancies, and helps to design and recommend chemotherapy regimens and supportive care plans. Additionally, he serves as the clinical content expert for the design of treatment plans in the network's Epic Beacon ordering system, which he continually helps update with new evidence-based treatment regimens. 

Marcus is also a member of the system's Pharmacy & Therapeutics Committee, where he presents new oncology agents for formulary addition and develops policies to ensure their safe and appropriate use. He subsequently develops and coordinates educational sessions for the pharmacy and nursing staff regarding new medications, and assists with reimbursement queries as needed. 

Laura S. Wood RN, MSN, OCN
Renal Cancer Research Coordinator 
Cleveland Clinic Taussig Cancer Center

Laura S. Wood RN, MSN, OCN, is the Renal Cancer Clinical Research Coordinator at the Cleveland Clinic Cancer Center in Cleveland, Ohio. She is involved in the care of patients with renal and genitourinary cancers. Laura is also a member of the Protocol Review and Monitoring Committee, the Immunotherapy Education Committee, and the Immune-Related Adverse Event Tumor Board.

Laura completed both her bachelor’s and master’s degrees in nursing from Kent State University in Kent, Ohio. She is active in the local and national Oncology Nursing Society, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer. A national and international lecturer on topics related to oncology nursing, Laura has authored many book chapters and journal articles on therapeutic approaches and nursing care in the management of cancer. Laura was the recipient of the 2012 Oncology Nursing Society Clinical Lectureship Award.

Target Audience

The target audiences for this initiative include oncology pharmacists, oncology nurses, nurse practitioners and nurse navigators actively engaged patient care. Other members of the care team may also participate.

Educational Objectives

Upon completing this activity, learners should be better able to:

  1. Review key updated guideline recommendations for treatment algorithms for patients with advanced genitourinary cancer
  2. Distinguish between targeted therapy and immunotherapy, and combination regimens with respect to treatment options in advanced genitourinary cancer
  3. Describe key components of patient education and communication concerning targeted therapy, immunotherapy, and combination immuno/VEG-F therapy for advanced genitourinary cancer
  4. Develop strategies for managing treatment-related toxicities including interprofessional care of patients receiving targeted and immunotherapy and combination regimens for advanced genitourinary cancer


Joint Accreditation StatementIn support of improving patient care, American Academy of CME, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to pride continuing education for the health care team.


acpeThis activity provides 1.5 ACPE contact hours (0.15 CEUs) of continuing education credit. Universal Activity Number JA4008191-0000-20-007-H01-P, Application


Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are able to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Faculty Educators

Marcus Flores, PharmD, BCPS, BCOP
No relevant financial relationships with any commercial interests.

Laura S. Wood, RN, MSN, OCN
Ms. Wood discloses the following:

  • Advisory Board for Marketing Purposes: Eisai
  • Promotional Speaker's Bureau: Bristol Myers Squibb, Merck, Pfizer

Planning Committee

John JD Juchniewicz, MCIS, CHCP; Edward Moylan, RPh; Natalie Kirkwood, JD, BSN; RN Wendy Gloffke, PhD; Paul Miniter, MS - No relevant financial relationships with any commercial interests.

This e-monograph will discuss investigational uses of agents.


The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CE credit for your participation, please complete the post-test (achieving a passing grade of 70% or greater), and program evaluation. Your certificate can be printed immediately.

For pharmacists, a statement of credit will be issued through CPE Monitor in 6-8 weeks. Only pharmacist learners who provided valid NABP e-Profile ID numbers and month and day of birth (MMDD) will be submitted to CPE Monitor for official record of credit.

Hardware/Software Requirements

Please ensure the computer you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection:Cable, High-speed DSL & any other medium that is internet accessible
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft Powerpoint, Flash Player & HTML5


For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm


For any questions, please contact: CEServices@academycme.org


© 2020. This CPE/CNE-certified activity is held as copyrighted © by American Academy of CME, Inc. Through this notice, the Academy grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).